Gapping up
In reaction to earnings/guidance:
In reaction to earnings/guidance:
- ASX +1.3% (Nov Sales)
Other news:
- CI +13.9% (announces significant increase to share repurchase program of $10 billion; reaffirms outlook)
- PSTX +13.6% (Positive Early Results from its Phase 1 Trial of Allogeneic CAR-T P-BCMA-ALLO1 in Relapsed-Refractory Multiple Myeloma at the 65th American Society of Hematology (ASH) Annual Meeting)
- MOR +8.7% (Pelabresib Improves All Four Hallmarks of Myelofibrosis in Phase 3 MANIFEST-2 Study)
- BLUE +5.6% (presents Long-Term Data Presented at ASH Support beti-cel as a Potentially Curative Gene Therapy for ß-Thalassemia Patients Who Require Regular Transfusions Through Achievement of Durable Transfusion Independence and Normal or Near-Normal Adult Hb Levels; reports Long-term Follow-up Data From bluebird's Gene Therapy Program in Sickle Cell Disease Support Durable Potentially Curative Benefits Through Stable Production of Anti-Sickling Adult Hemoglobin and Resolution of Vaso-Occlusive Events)
- CRVS +5.2% (Presents New Interim Soquelitinib Data from its Phase 1/1b T Cell Lymphoma Trial)
- NKTX +4% (Presents NKX101 Clinical Data at the 2023 American Society of Hematology Annual Meeting & Exposition)
- KROS +3.2% (Presents Clinical Data from its KER-050 Program at the 65th American Society of Hematology Annual Meeting and Exposition)
- RLYB +2.4% (Presents Natural History Study for Fetal and Neonatal Alloimmune Thrombocytopenia at the 65th American Society of Hematology Annual Meeting)
- ORTX +1.4% (announces that the Swiss Agency for Therapeutic Products has approved Libmeldy for the treatment of early-onset metachromatic leukodystrophy)
- SNDX +1.2% (Incyte and Syndax (SNDX) Present Additional Data from Positive AGAVE-201 Trial at ASH Plenary Session Showing Axatilimab Efficacy Including Durable Responses in Chronic Graft-Versus-Host Disease; Announces Positive Data for Revumenib in Patients with Acute Leukemias from the BEAT AML SAVE AML and AUGMENT-102 Phase 1 Combination Trials)
- IPHA +1.2% (Presents Positive Results From TELLOMAK Phase 2 Study With Lacutamab in Patients With Sézary Syndrome at ASH 2023)
- AXSM +1.2% (Presents New Data and Post-Hoc Analyses of Auvelity in Patients with Major Depressive Disorder at the American College of Neuropsychopharmacology (ACNP) 2023 Annual Meeting)
- MFC +1% (has agreed to reinsure to Global Atlantic four blocks of legacy/low ROE business including $6 billion of long-term care reserves)
Analyst comments:
- DLO +2.7% (upgraded to Equal Weight from Underweight at Barclays)
- AVTR +2.6% (upgraded to Outperform from Market Perform at TD Cowen)
- BBY +2.3% (upgraded to Buy from Hold at Jefferies)
- FTRE +2.1% (upgraded to Buy from Neutral at Citigroup)
- ABBV +1.2% (upgraded to Buy from Neutral at Goldman)
- EQH +1% (upgraded to Buy from Hold at Jefferies)